Last updated: June 1, 2026
What suppliers make RYTELO (rolapitant) active pharmaceutical ingredient (API) and finished drug product?
RYTELO is the branded oral NK1 (substance P) receptor antagonist rolapitant. Supplier mapping for RYTELO requires the specific API manufacturer and the contract manufacturers behind the marketed dosage form, which are typically disclosed in FDA regulatory submissions and in the drug product’s labeling/manufacturing sections.
The available information in this request does not include:
- the exact RYTELO dosage form referenced (tablet strength and presentation),
- the FDA application number (NDA/BLA),
- the FDA “Drug Label Information”/CGMP manufacturing statement text,
- Orange Book “manufacturing site” and patent listing entries tied to the finished product.
Because supplier identification depends on those primary records, a complete and accurate supplier list cannot be produced from the information provided.
Which companies are listed as RYTELO (rolapitant) manufacturers on FDA labeling and Orange Book?
For branded drugs, FDA labeling typically lists:
- “Manufactured for” or “Distributed by” (label holder),
- “Manufactured by” and the site(s) for the finished dosage form.
Orange Book listings (when queried for the specific NDA product) may also help connect:
- the drug product’s NDA strength/form,
- approved manufacturers and changes.
The request provides no Orange Book NDA entry, product strength, or label “Manufactured by” text, so supplier names cannot be stated without risking inaccuracy.
How do contract manufacturing and packaging suppliers for RYTELO differ by dosage strength?
For oral NK1 antagonists, the supply chain may split by:
- API manufacturing site(s),
- tableting granulation steps,
- coating, printing/packaging,
- bottle/blister packing.
But supplier differentiation requires the site-level manufacturing statements tied to the specific marketed strength and package configuration. This data is not present in the request.
What is the RYTELO manufacturing supply chain for tablets: API sourcing, intermediates, and final fill-finish?
Tablet supply chains typically involve:
- rolapitant API (or key intermediate) sourcing,
- excipient procurement,
- tablet compression/coating,
- packaging into bottles or blisters.
A supplier map must be built from:
- FDA CMC sections and inspection-relevant information,
- labeling manufacturing statements,
- and site-specific histories.
Those primary documents are not included here.
What Orange Book status does RYTELO have, and does it affect supplier availability?
Orange Book status drives:
- whether approved generics can enter,
- whether additional manufacturers exist for AB-rated products,
- and whether manufacturing networks expand.
The request does not include the Orange Book entry for RYTELO, so the exclusivity and manufacturer count cannot be linked to supplier availability.
Which generic or biosimilar entrants could change RYTELO supplier dynamics?
RYTELO is a small molecule; biosimilars do not apply. If generic approvals exist, they can add new:
- finished dosage manufacturers,
- API sources,
- and packaging suppliers.
But identifying entrant manufacturers requires the Orange Book generic list for the specific NDA strength/form. No Orange Book data is provided.
Key Takeaways
- RYTELO supplier identification (API and finished product manufacturing/packaging) cannot be completed from the information provided.
- Accurate supplier names depend on the specific NDA product strength and the FDA labeling and Orange Book manufacturing-site statements.
- Without those primary identifiers, any supplier list would be incomplete or potentially incorrect.
FAQs
-
What does RYTELO manufacture by information on the label typically show?
It usually lists “Manufactured by” sites and sometimes “Manufactured for/Distributed by” entities for the finished product.
-
Where can API suppliers for RYTELO be verified in regulatory records?
API and intermediate manufacturing are typically found in FDA CMC sections tied to the approved NDA and manufacturing site supplements.
-
Does RYTELO’s API have multiple approved sources?
Multi-source API is possible for many small molecules, but the number must be verified against the NDA manufacturing changes and site listings.
-
How do packaging suppliers show up for tablet brands like RYTELO?
Packaging steps are usually reflected in label manufacturing statements and FDA supplement records, but the exact packager is strength and site specific.
-
Do Orange Book entries include manufacturing sites for RYTELO?
Orange Book primarily ties drugs to patents/Exclusivity and lists approved product details; site-level manufacturing data may require cross-referencing labeling and FDA CMC disclosures.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- FDA Drug Labeling (RxNorm/Drug Label information and labeling PDFs). https://dailymed.nlm.nih.gov/dailymed/
